



2015 Radio Program Sponsorship Agreement

This agreement defines the terms and conditions under which funding from Cephalon, Inc. d/b/a Teva Pharmaceuticals ("Teva") will be accepted and utilized by Algiatry, LLC ("Algiatry") for sponsorship of the Aches and Gains™ radio program ("Program") as further described in Exhibit A, attached hereto. Teva and Algiatry agree to the following:

1. The Program is for the purpose of scientific and medical education and exchange of information consistent with enhancing patient care ("Purpose"). The Program is not intended to promote any specific proprietary business interest of Teva or any other pharmaceutical company.
2. Teva shall pay \$50,000 (fifty thousand US dollars) for sponsorship of the Program ("Sponsorship"). The funds provided by Teva shall be used to support the production of the Program consistent with its educational/scientific goals, including, but not limited to, marketing and advertising costs and other tax and legal requirements. No Teva monies may be used directly for any other purpose.
3. To the extent that Algiatry makes, coordinates or develops any content relating to the Program ("Content") such Content shall be developed completely independently of Teva and any other pharmaceutical company. Accordingly, Algiatry has sole responsibility for and control over the Content, including the selection of topics and speakers and agrees to conduct such activities objectively at the highest scientific standard. If Algiatry is aware that it is discussing a Teva product and the Teva product is the subject of substantial discussion of the Content, Algiatry will take reasonable steps to ensure that both favorable and unfavorable information about such product will be fairly represented and that there is a balanced discussion of the prevailing body of scientific information (including limitations on data) on the product and therapeutic area. In the event Algiatry includes any discussion of unapproved or unlabeled use of any Teva product, such facts shall be disclosed to the audience, there will be a sound scientific basis for including such a discussion, and Algiatry shall discuss any applicable safety and health risks in connection with such use. Teva will not be permitted to participate in any committee, forum, one-on-one meeting or other activity, where Content development for the Program could be discussed. The individuals invited to appear on the Program will be selected by Algiatry.
4. Teva's Sponsorship shall be acknowledged with communications to the public in the same manner as other sponsors at the same level of sponsorship.
5. Sponsorship includes the benefits described in Exhibit A ("Sponsorship Benefits"). Teva shall provide Algiatry with a list of its promoted products in the CNS therapeutic area on Exhibit B.
6. Algiatry and Teva will conduct all activities pursuant to this agreement and related to the Sponsorship in accordance with all applicable laws, regulations, and guidances.

By signing below and accepting the Sponsorship, Algiatry agrees to the terms and conditions of this Radio Program Sponsorship Agreement

Algiatry Authorized Signature *Paul J. Christof*
 Name: Paul J. Christof
 Date: 4/24/15

LEGAL AFFAIRS

PLAINTIFF TRIAL EXHIBIT P-24081_00001

Exhibit A



April 13, 2015

Dear Matthew,

I'm a pain specialist at The Johns Hopkins Hospital and I host the first radio talk show on overcoming pain, called **Aches and Gains**. The show is nationally syndicated and airs on Sirius XM Radio with an estimated listenership of 13 million on Family Talk 131. My biography, guests, and show archives can be found at www.paulchristomd.com.

Aches and Gains provides hope for those suffering from pain through interviews with patients, specialists, authors, and celebrities who have conquered their pain.

The shows consist of two, 30 minute segments (60 minutes total), and airs every Saturday from 5-6 pm Eastern. SIRIUS XM offers online access to subscribers, and all shows are archived on the Aches and Gains website.

I'm reaching out to you for continued support of the Aches and Gains Radio Program in the amount of \$50,000. Support provides company mention at the top of the hour for every show, and a 15 sec. description of the company for every show during the first break. All supporters are listed on the radio show page with links to their organization.

I look forward to hearing from you, and thank you very much.

Sincerely,

Paul J. Christo, M.D.

Exhibit B
CURRENTLY PROMOTED TEVA CNS PRODUCTS

ACTIQ® (fentanyl citrate) oral transmucosal lozenge [C-II]
AMRIX® (cyclobenzaprine hydrochloride extended-release capsules)
AZILECT® (rasagiline tablets)
COPAXONE® (glatiramer acetate injection)
FENTORA® (fentanyl buccal tablet)[C-II]
GABITRIL® (tiagabine HCl)
NUVIGIL® (armodafinil) Tablets [C-IV]
PROVIGIL® (modafinil) Tablets [C-IV]
ZECURITY® (sumatriptan iontophoretic transdermal system)



2015 Radio Program Sponsorship Agreement

This agreement defines the terms and conditions under which funding from Cephalon, Inc. d/b/a Teva Pharmaceuticals ("Teva") will be accepted and utilized by Algiatry, LLC ("Algiatry") for sponsorship of the Aches and Gains™ radio program ("Program") as further described in Exhibit A, attached hereto. Teva and Algiatry agree to the following:

1. The Program is for the purpose of scientific and medical education and exchange of information consistent with enhancing patient care ("Purpose"). The Program is not intended to promote any specific proprietary business interest of Teva or any other pharmaceutical company.
2. Teva shall pay \$50,000 (fifty thousand US dollars) for sponsorship of the Program ("Sponsorship"). The funds provided by Teva shall be used to support the production of the Program consistent with its educational/scientific goals, including, but not limited to, marketing and advertising costs and other tax and legal requirements. No Teva monies may be used directly for any other purpose.
3. To the extent that Algiatry makes, coordinates or develops any content relating to the Program ("Content") such Content shall be developed completely independently of Teva and any other pharmaceutical company. Accordingly, Algiatry has sole responsibility for and control over the Content, including the selection of topics and speakers and agrees to conduct such activities objectively at the highest scientific standard. If Algiatry is aware that it is discussing a Teva product and the Teva product is the subject of substantial discussion of the Content, Algiatry will take reasonable steps to ensure that both favorable and unfavorable information about such product will be fairly represented and that there is a balanced discussion of the prevailing body of scientific information (including limitations on data) on the product and therapeutic area. In the event Algiatry includes any discussion of unapproved or unlabeled use of any Teva product, such facts shall be disclosed to the audience, there will be a sound scientific basis for including such a discussion, and Algiatry shall discuss any applicable safety and health risks in connection with such use. Teva will not be permitted to participate in any committee, forum, one-on-one meeting or other activity, where Content development for the Program could be discussed. The individuals invited to appear on the Program will be selected by Algiatry.
4. Teva's Sponsorship shall be acknowledged with communications to the public in the same manner as other sponsors at the same level of sponsorship.
5. Sponsorship includes the benefits described in Exhibit A ("Sponsorship Benefits"). Teva shall provide Algiatry with a list of its promoted products in the CNS therapeutic area on Exhibit B.
6. Algiatry and Teva will conduct all activities pursuant to this agreement and related to the Sponsorship in accordance with all applicable laws, regulations, and guidances.

By signing below and accepting the Sponsorship, Algiatry agrees to the terms and conditions of this Radio Program Sponsorship Agreement

Algiatry Authorized Signature *Paul J. Christof*
 Name: Paul J. Christof
 Date: 4/24/15

LEGAL AFFAIRS